ViaCyte is a biotechnology company using stem cells to create pancreatic beta cell precursors for treating diabetes that is headquartered in San Diego, California and was founded in 1999 by Paul Laikind.
Timeline
June 19, 2021
ViaCyte raises $45M in Series D funding.
The round includes participation from existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, Adage Capital Partners, Invus Group, Asymmetry Ventures, and Artis Ventures.
June 18, 2021
ViaCyte raises a $45,000,000 series D round.
May 26, 2020
ViaCyte raises a $27,000,000 series D round.
March 2020
ViaCyte raises a $32,600,000 series D round from Bain Capital Life Sciences, RA Capital Management, Sanderling Ventures and TPG Capital Asia.
November 2018
ViaCyte raises a $80,000,000 series D round from Bain Capital Life Sciences, RA Capital Management, Sanderling Ventures and Texas Pacific Group.
September 2018
ViaCyte raises a $10,000,000 convertible note from W. L. Gore and Associates.
December 2017
ViaCyte raises a $1,400,000 grant from California Institute for Regenerative Medicine.
July 2016
ViaCyte raises a $3,900,000 grant.
September 2014
ViaCyte raises a $16,600,000 grant from California Institute for Regenerative Medicine.
August 2014
ViaCyte raises a $5,400,000 series C round.
Page 1 of 2
Funding rounds
SBA Awards
People
Name
Role
LinkedIn
Further reading
Title
Author
Link
Type
Date
$10 Million Grant to ViaCyte from Gore Supports Cell-Based Treatment for Diabetes
Beyondtype1
Web
Center for Beta Cell Therapy in Diabetes and ViaCyte Announce Start of European Clinical Trial of Human Stem Cell-derived Implants in Type 1 Diabetes Patients
ViaCyte, Inc.
Web
CRISPR Therapeutics and Viacyte launch diabetes partnership
BIOCOM AG
Web
ViaCyte encapsulated islet cells show survival success in type 1 diabetes trial
Benedict Jephcote
Web
ViaCyte Secures $80 Million Financing to Advance Functional Cures for Insulin-Requiring Diabetes
ViaCyte, Inc.
Web
Documentaries, videos and podcasts
Title
Date
Link
Companies
Company
CEO
Location
Products/Services
News
Title
Author
Date
Publisher
Description
Emmy Lucas
September 13, 2021
FierceBiotech
Months after raising $45 million and losing a chief scientific officer, stem cell-focused biotech ViaCyte has restaffed the position with a cell therapy academic from the University of British Columbia. Timothy Kieffer will join the clinical-stage regenerative medicine biotech as CSO.
ViaCyte, Inc.
June 25, 2021
www.prnewswire.com:443
/PRNewswire/ -- ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing cell therapies that provide a functional cure for patients...
FinSMEs
June 19, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Kyle LaHucik
June 9, 2021
FierceBiotech
ViaCyte snagged $45 million in a new tranche of financing to expand on a 2018 series D worth $80 million. The money will fund the biotech's work on two midstage candidates for type 1 diabetes, and it comes just a day after the biotech said its chief scientific officer is leaving.
BioSpace
June 8, 2021
BioSpace
ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing cell therapies that provide a functional cure for patients with diabetes, announced the appointment of ViaCyte's current Vice President of Translation Research Evert Kroon, PhD, to serve as interim Chief Scientific Officer following the departure of CSO Kevin D'Amour, PhD.
ViaCyte, Inc.
January 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- ViaCyte, Inc., a clinical-stage regenerative medicine company, today announced the appointment of Michael Yang to President and CEO and as a...
BioSpace
May 28, 2020
BioSpace
ViaCyte, Inc. , a privately held regenerative medicine company, announced today that ViaCyte's President and CEO Paul Laikind , Ph.D. is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 10 a.m. Eastern Time in Track 9. The company recently announced a $27 million financing to advance
FinSMEs
May 26, 2020
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Is a
CompanyCompany attributes
Biotechnology
Biomedical engineering
Regenerative medicine
Stem cellLocation
San DiegoCompany status
Active
B2X
B2BCEO
Paul LaikindCrunchbase
Legal name
ViaCyte, Inc.
Date incorporated
December 20, 1999
Number of Employees (ranges)
50 – 99
Full address
3550 General Atomics Court San Diego, CA 92121
CIK number
California Institute for Regenerative Medicine
W. L. Gore and Associates
Bain Capital Ventures
National Institute of Diabetes and Digestive and Kidney Diseases
Johnson & Johnson Innovation
Texas Pacific GroupDUNS Number
791779838
Founded date
1999
Email address
info@viacyte.com
Total funding amount (USD)
361,400,000
Latest funding round date
June 18, 2021
Latest funding type
Other attributes
Country
United StatesCategories
Related Topics
Contributors
- 1
Dawson Sewell
Writing about startups. - 2
Aime Anne Nisay
QA Engineer of web and mobile applications - 3
Melanie Manipula
Helping organize knowledge. - 4
Meredith Hanel
Medical Genetics PhD, following life science applications that improve the health of humans and our planet. - 5
Amit Gehlot
Influencer + Btech from RTU, Surfing on Internet. I like to learn new things + Travel + Foody. - 6
Erin Scherfner
loading information... - 7
Reys Phillips
A graduate of Cleveland State University with a Bachelor of Science in Education. My main hobbies include story writing and reading. - 8
Henry Ogolla
Passionate about reading and writing. - 9
Neelam Jhaveri
Techno Geek + Gamer + Fashionista + Sense of Humor = It's ME - 10
Jason D. Rowley
Former Data Acquisition Lead @ Golden (Recursion Inc.). Excited about open knowledge and pulling the future forward.